Multiple-Dose Safety in Japanese Subjects With Mild-to-Moderate Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2010
At a glance
- Drugs Solanezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly
- 11 Jul 2010 Results presented at the Alzheimer's Association International Conference on Alzheimer's Disease.
- 22 Jul 2009 Actual patient number (33) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Actual end date (July 2009) added as reported by ClinicalTrials.gov.